Onco Wiki / Biomarker

BCL2-Ausdruck durch IHC

Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.

IDBIO-BCL2-EXPRESSION-IHC
ArtBiomarker
Aliase
B-Zell-Lymphom 2BCL2BCL2-Expression durch ImmunhistochemieЕкспресія BCL2 (імуногістохімія)
Statusreviewed 2026-04-25 | pending_clinical_signoff
ErkrankungenDIS-AML DIS-CLL DIS-DLBCL-NOS DIS-FL DIS-MCL
QuellenSRC-NCCN-BCELL-2025

Biomarker-Fakten

Biomarker-Typprotein_expression_ihc
Messung
VerfahrenIHC zur FFPE-Biopsie (Anti-BCL2-Antikörper, 124 Klon)
Einheitencategorical (positive ≥50% | negative); semi-quantitative percentage often reported
Verwandte BiomarkerBIO-BCL2-REARRANGEMENT BIO-DOUBLE-HIT

Anmerkungen

Cross-disease relevance: - **CLL/SLL**: BCL2-dependent — venetoclax (BCL-2 inhibitor) is highly active. Universal CLL marker; drives VenO 1L choice for high-risk. - **MCL**: cyclin-D1+ MCL is also BCL2+; predicts venetoclax-rituximab sensitivity in r/r — emerging 2L+ pathway. - **FL**: defining via t(14;18) IGH/BCL2 (~85%) — over-expression blocks apoptosis. Tazemetostat (EZH2 inhibitor) emerging in EZH2-mut r/r FL. - **DLBCL**: double-expressor (BCL2+ ≥50% IHC + MYC+ ≥40% IHC at protein level, distinct from FISH double-hit) is adverse but does NOT change 1L regimen per current evidence. - **HGBL-DH**: BCL2 rearrangement is part of double-hit definition (with MYC + optionally BCL6). - **MM**: t(11;14) MM subset highly venetoclax-sensitive; emerging therapy. Direct algorithm-driving currently: indirectly via BIO-DOUBLE-HIT in HGBL-DH + via venetoclax-eligible flag in CLL high-risk. Future: drive r/r 2L+ venetoclax pathway across all BCL2-dependent diseases.

Verwendet von

Therapeutische Relevanz

Biomarker

Kapitel des Handbuchs

Anwendungsgebiet

Fragebogen